Amivantamab in patients with EGFR Ex20ins-mutated NSCLC

Amivantamab in patients with EGFR Ex20ins-mutated NSCLC

REZILIENT1: zipalertinib, a novel EGFR TKI, in NSCLC with ex20ins mutationsПодробнее

REZILIENT1: zipalertinib, a novel EGFR TKI, in NSCLC with ex20ins mutations

Amivantamab and lazertinib in treatment-naïve EGFR-mutant NSCLCПодробнее

Amivantamab and lazertinib in treatment-naïve EGFR-mutant NSCLC

Dr Reckamp on Amivantamab in EGFR Exon 20–Mutated NSCLCПодробнее

Dr Reckamp on Amivantamab in EGFR Exon 20–Mutated NSCLC

PROs in PAPILLON trial: amivantamab + chemo for EGFR Exon 20 NSCLCПодробнее

PROs in PAPILLON trial: amivantamab + chemo for EGFR Exon 20 NSCLC

PAPILLON Phase III primary results: amivantamab + chemo vs chemo in EGFR Exon 20 NSCLCПодробнее

PAPILLON Phase III primary results: amivantamab + chemo vs chemo in EGFR Exon 20 NSCLC

Current treatments and challenges for patients with EGFR exon 20 insertion-positive NSCLCПодробнее

Current treatments and challenges for patients with EGFR exon 20 insertion-positive NSCLC

CHRYSALIS: Amivantamab for EGFR exon 20 insertion mutant NSCLCПодробнее

CHRYSALIS: Amivantamab for EGFR exon 20 insertion mutant NSCLC

Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLCПодробнее

Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC

Phase III MARIPOSA: amivantamab + lazertinib vs osimertinib in EGFR-mutated NSCLCПодробнее

Phase III MARIPOSA: amivantamab + lazertinib vs osimertinib in EGFR-mutated NSCLC

Amivantamab combo with lazertinib favourable in post-osimertinib EGFR-mutant NSCLCПодробнее

Amivantamab combo with lazertinib favourable in post-osimertinib EGFR-mutant NSCLC

ASCO 2021 Lung Recap: Amivantamab and Mobocertinib for EGFR Exon 20Подробнее

ASCO 2021 Lung Recap: Amivantamab and Mobocertinib for EGFR Exon 20

Expert video report on amivantamab in combination therapy for 1L treatment in EGFRm, advanced NSCLCПодробнее

Expert video report on amivantamab in combination therapy for 1L treatment in EGFRm, advanced NSCLC

PALOMA-3: subcutaneous vs intravenous amivantamab + lazertinib in refractory EGFR-mutated NSCLCПодробнее

PALOMA-3: subcutaneous vs intravenous amivantamab + lazertinib in refractory EGFR-mutated NSCLC

Amivantamab for NSCLC with MET Exon 14 skipping mutationsПодробнее

Amivantamab for NSCLC with MET Exon 14 skipping mutations

Amivantamab and Mobocertinib for EGFR Exon-20 Disease - Lung Cancer Video LibraryПодробнее

Amivantamab and Mobocertinib for EGFR Exon-20 Disease - Lung Cancer Video Library

EGFR Exon 20 Mutations in Non–Small Cell Lung CancerПодробнее

EGFR Exon 20 Mutations in Non–Small Cell Lung Cancer

Amivantamab in combination with lazertinib for osimertinib-relapsed, chemo-naïve EGFRm NSCLCПодробнее

Amivantamab in combination with lazertinib for osimertinib-relapsed, chemo-naïve EGFRm NSCLC

Highlights on amivantamab after progression on osimertinib in EGFR-mutated NSCLC: MARIPOSA-2Подробнее

Highlights on amivantamab after progression on osimertinib in EGFR-mutated NSCLC: MARIPOSA-2

PAPILLON: amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertionsПодробнее

PAPILLON: amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions

From clinic to practice in NSCLC patients with exon 20 mutationsПодробнее

From clinic to practice in NSCLC patients with exon 20 mutations